604 Views

Instructional Course

Instructional Course - Available with the Platinum and Silver packages or Individual Course Ticket

083IC - Active Surveillance 2022

Monday, May 16, 2022

1:30 PM – 3:30 PM

Location: Room 204

Instructional Course Director(s)

Laurence H. Klotz, MD

University of Toronto

Instructional Course Faculty(s)

Mark Emberton, MD

University College London
Ian Murchie Thompson, Jr., MD

President and Chief Development Officer
The University of Texas Health Science Center at San Antonio
DT

Derya Tilki, MD

University Hospital Hamburg-Eppendorf

Learning Objectives:

Summarize the developments regarding the molecular characterization of low grade prostate cancer.
Identify the role and limitations of magnetic resonance imaging (MRI) and other advanced imaging techniques, including micro ultrasound and prostate specific membrane antigen (PSMA) positron emission tomography (PET).
Utilize existing molecular biomarkers and have an awareness of biomarkers in the pipeline.
Identify several innocuous interventions which may reduce the risk of progression in men on surveillance, including exercise, statins, vitamin D, metformin and dietary modification.

Active surveillance has become the standard of care for most men with low risk and some with intermediate risk prostate cancer. The field has developed rapidly over the last few years, with enhanced understanding of the molecular genetics of Gleason 3 vs higher grade cancer, the incorporation of advanced imaging techniques and molecular biomarkers, and the option of focal therapy with ongoing surveillance of the untreated prostate tissue. A number of innocuous interventions to reduce the likelihood of progression have also been described. This course will summarize these advances with an emphasis on practical applications in clinical practice.